DURHAM, N.C., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that Joan C. Winterbottom will join the company as chief human resources officer.
Ms. Winterbottom has 14 years of experience in human resources in the pharmaceutical and biotechnology industries. She most recently served as senior vice president of human resources at Amicus Therapeutics. She was also senior vice president of human resources at Savient Pharmaceuticals and held several positions in human resources at Johnson & Johnson, most recently vice president of human resources for global OTC, nutritionals, and wellness and prevention. She completed the graduate certificate program for organizational development at Saint Joseph's University in Philadelphia and holds a B.S. in business and economics from Lehigh University.
"Argos presents a unique opportunity for any biopharmaceutical professional, but especially in my role as chief human resources officer because the company is experiencing such tremendous growth," said Ms. Winterbottom. "I look forward to working to bring more top talent to Argos and promoting the culture of innovation and dedication to patients that has been established here."
"We are making exciting progress in our effort to build Argos into a fully integrated commercial oncology company and we are especially pleased to be planning our expansion right here in Durham," said Jeff Abbey, president and CEO of Argos. "With her outstanding experience, Joan is the ideal person to lead our human resources efforts through all phases of our growth in the years ahead."
About the Arcelis® Technology Platform
Arcelis® is a fully personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient's disease. It is designed to overcome immunosuppression by producing a durable memory T-cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers, as well as infectious diseases, and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies. The Arcelis® process uses only a small tumor or blood sample and the patient's own dendritic cells, which are collected and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease antigens. The activated, antigen-loaded dendritic cells are then formulated into the patient's plasma and administered via intradermal injection.
About Argos Therapeutics
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The Company is also developing Arcelis®-based product candidate AGS-004 for the treatment of HIV, currently being evaluated in a phase 2 clinical trial in combination with a latency reversing drug for HIV eradication in adult patients. For more information about Argos Therapeutics, visit www.argostherapeutics.com.
Forward Looking Statements
Any statements in this press release about Argos' future expectations, plans and prospects, including statements about Argos and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including whether Argos' cash resources will be sufficient to fund our continuing operations for the period anticipated; whether results obtained in clinical trials will be indicative of results obtained in future clinical trials; whether Argos' product candidates will advance through the clinical trial process on a timely basis and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if product candidates obtain approval, they will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of Argos' Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 which is on file with the SEC. In addition, the forward-looking statements included in this press release represent Argos' views as of February 24, 2015. Argos anticipates that subsequent events and developments will cause Argos' views to change. However, while Argos may elect to update these forward-looking statements at some point in the future, Argos specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Argos' views as of any date subsequent to February 24, 2015.
Source:Argos Therapeutics, Inc.